debt_leverage_profile
0.01x Total Debt / Equity (Conservative)
High
SEC-XBRL
interest_rate_sensitivity
Low direct sensitivity; minimal revenue-generating debt, but rising rates increase cost of equity financing critical for clinical-stage biotech burn rate funding
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
API synthesis from Chinese CMOs and Indian API manufacturers represent primary chokepoints for OT-101 and small-molecule candidates
Inferred
Agent_Inference
international_expansion_readiness
Minimal international revenue; preclinical/clinical stage means negligible FX exposure; USD-denominated NIH/grant funding dominates
Inferred
Agent_Inference
geographic_footprint
Effectively US-only operational revenue; no material sovereign currency devaluation risk given pre-commercial stage across all geographies
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Single CRO dependency risk is high; contract research organizations conducting Phase II/III trials are non-substitutable mid-trial without FDA notification
Inferred
Agent_Inference
business_model_type_primary
Cloud infrastructure termination would minimally impact operations; primary work is lab-based and CRO-outsourced, not cloud-dependent SaaS
Inferred
Agent_Inference
business_model_type_secondary
Clinical data management platforms (e.g., Medidata, Veeva) pose higher lock-in risk than generic cloud providers for trial integrity
Inferred
Agent_Inference
switching_cost_profile
Moderate API coupling risk via clinical data systems; switching EDC platforms mid-trial requires FDA amendment, creating 6-12 month delays
Inferred
Agent_Inference
howey_test_risk_index
Revenue model is grant/licensing-based, not investment contracts; Howey Test largely inapplicable; equity securities are standard registered shares
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Clinical trial patient data subject to HIPAA primarily; GDPR exposure exists for any EU trial sites; CCPA exposure minimal given no consumer product
Inferred
Agent_Inference
antitrust_exposure_flag
Negligible antitrust risk; single-asset oncology developer with sub-$50M market cap holds no market power in any therapeutic segment
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
Approximately 0% recurring subscription revenue; 100% transactional via grants, licensing milestones, and NIH funding tranches
Inferred
Agent_Inference
monetization_vector
Primary monetization via future drug licensing royalties and milestone payments; currently grant-funded with no commercial product revenue
Inferred
Agent_Inference
pricing_architecture
No commercial pricing architecture exists; future pricing will follow oncology biologics benchmark ($10K-$30K/month treatment course)
Inferred
Agent_Inference
pricing_power_rating
Potential high pricing power if OT-101 achieves orphan/breakthrough designation; oncology drugs command premium reimbursement with limited substitutes
Inferred
Agent_Inference
target_gross_margin_bracket
Post-commercialization gross margin target 80-90%, consistent with licensed biologic royalty structures; current gross margin effectively negative
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider leakage problem; pre-commercial stage with no customer base; IP protection via patents mitigates future free-rider risk
Inferred
Agent_Inference
headcount_cost_structure
Revenue growth is headcount-sublinear; licensing and royalty model requires minimal incremental headcount; CRO outsourcing absorbs variable trial costs
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of revenue growth is CRO/CMO contract-based, not headcount-driven; doubling revenue via licensing requires minimal new internal hires
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; no franchise network exists
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC irrelevant pre-commercialization; post-launch oncologist adoption cost estimated $5K-$15K per prescriber via specialty sales force
Inferred
Agent_Inference
network_effect_present
No network effects present; pharmaceutical efficacy is independent of user base size; no platform or data network dynamics applicable
Inferred
Agent_Inference
asset_efficiency_ratio
91.7% Return on Assets (Outstanding)
High
SEC-XBRL
recession_resistance_tier
Moderate-high recession resistance for oncology therapeutics; cancer treatment demand is inelastic, but venture/grant funding may tighten in downturns
Inferred
Agent_Inference
customer_segment_primary
Primary future customer: oncologists and hospital formulary committees treating GBM and solid tumor patients; highly concentrated in academic medical centers
Inferred
Agent_Inference
customer_segment_secondary
Secondary customers: pharmaceutical licensing partners and co-development collaborators; single partner deal could represent 80%+ of near-term revenue
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
0.7% CapEx / Revenue (Low-CapEx Asset-Light)
High
SEC-XBRL
sec_cik
0000908259
High
SEC-EDGAR
ticker
OTLC
High
SEC-EDGAR